Jing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).
Jing Ai, MD
Advertisement
Articles by Jing Ai, MD
Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).
Advertisement
Latest Updated Articles
Dr. Ai on Single-Agent and Combination Therapy in Patients With MDSPublished: April 27th 2018 | Updated:
Dr. Ai on the Use of Hypomethylating Agents in Patients With MDSPublished: May 7th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
2
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
3
Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD
4
Enfortumab Vedotin Dose Reductions May Improve Tolerability Without Impeding OS in Advanced Urothelial Carcinoma
5